Skip to content

Krzysztof Pyrc

prof. Krzysztof Pyrc
Head of the Laboratory of Virology and Animal Facility
Malopolska Center of Biotechnology, Jagiellonian University
Phone: +48 12 664 61 21
E-mail: k.a.pyrc [AT] uj.edu.pl

Follow me on ResearchGate
Research interests

    • Virus entry
    • Novel antiviral drugs
    • 3D tissue cultures & organoids

    • 2021. The City of Krakow Prize.
    • 2021. Nicolaus Copernicus medal for outstanding scientific achievements by the Polish Academy of Sciences.
    • 2021. The "Promoter of Poland" title by the Poland-Now foundation.
    • 2021. Men of the Year by the Krakow Newspaper.
    • 2021. Top 100 people in medicine in Poland by the “Puls Medycyny” journal
    • 2020. Award of the Minister of Science and Higher Education for scientific achievements.
    • 2020. IMI2 101005077. Corona accelerated R&D in Europe (CARE). Horizon2020/IMI/Efpia
    • COST CA18238 (European transdisciplinary networking platform for marine biotechnology). 2018-2022. sMC member.
    • 2020-2022. NCN Opus. Metabolites of Baltic cyanobacteria as natural compound library for high throughput screening and the development of new antiviral drugs. KP: WP coordinator.
    • 2019-2022. Horizon2020. ITN networks. Organoids for Virus Research - An innovative training-ETN programme. PI for PL and WP coordinator: K Pyrc.
    • 2019-2021. NCN Opus. CP protease of the O'nyong-nyong virus: substrate profiling, design and synthesis of inhibitors and activity-based probes and their biochemical analysis. KP: WP coordinator.
      Subvention for work on the SARS2 coronavirus. Ministry of Science. KP: PI.
    • COST CA17103 (Delivery of Antisense RNA Therapeutics). 2018-2022. MC member.
    • COST CA17108 (Aedes Invasive Moquitoes). 2018-2022. MC member.
    • 2018. NCN Opus. Cellular proteases during coronaviral infection. PI: K Pyrc.
    • 2016: Zika virus NS3 protease. Research grant from The National Science Centre (PI: Krzysztof Pyrc). Opus funding scheme in consortia with University of Science and Technology in Krakow.
    • 2014: prof. Bassalik award for the publication "Staphylococcus aureus proteases degrade lung surfactant protein A potentially impairing innate immunity of the lung".
    • 2013: Individual award of the President of the Jagiellonian University.
    • 2013: Coronavirus and the cell: dyplomatic bag. Research grant from The National Science Centre (PI: Krzysztof Pyrc). Sonata Bis funding scheme.
    • 2012: Scholarship from the Ministry of Science and Higher Education.
    • 2011: Mechanism of HCoV-NL63 / HCoV-HKU1 infection. Extension of the Iuventus Plus grant from the Ministry of Science and Higher Education (PI: Krzysztof Pyrc).
    • 2011: Individual award of the President of the Jagiellonian University.
    • 2011: Invitation to join the Plos ONE editorial board
    • 2011: Porphyromonas gingivalis: natural defense and regulatory mechanisms. Research grant from The National Science Centre (PI: Krzysztof Pyrc)
    • 2011: Novel oncolytic vectors. Lider grant from The National Centre for Research and Development (PI: Krzysztof Pyrc).
    • 2010: Mechanism of HCoV-NL63 / HCoV-HKU1 infection. Iuventus Plus grant from the Ministry of Science and Higher Education (PI: Krzysztof Pyrc).
    • 2010: Extension of the HOMING PROGRAMME (Reintegration Grant For Polish Scientists). Foundation for Polish Science. 09.2010-09.2011 (PI: Krzysztof Pyrc).
    • 2010: Enzymes produced by Porphyromonas gingivalis as virulence factors and potential targets for drug development against periodontitis, rheumatoid arthritis, atherosclerosis and aspiration pneumonia. Foundation for Polish Science (PI prof Jan Potempa; Aspiration pneumonia WP coordinator: Krzysztof Pyrc)
    • 2009: „HexaPrime as a new method for identification of RNA viruses” Research grant from Ministry of Science and Higher Education (PI: Krzysztof Pyrc).
    • 2009: industrial grant together with commercial entities.
    • 2009: „Molecular Biotechnology for Health” within the EU structural funds/POIG 2.1 programme.
    • 2008 - "Polityka" Foundation Award/Stipend.
    • 2008 - HOMING PROGRAMME (Reintegration Grant For Polish Scientists) from from Foundation of Polish Science (PI: Krzysztof Pyrc).
    • 2008 - stipend within the START PROGRAMME from Foundation of Polish Science, for the most promising young researchers.
    • 2008 - PhD thesis award of the Infectious Diseases Society of the Netherlands, for the best PhD thesis in years 2005-2007 in the Netherlands.
    • 2006 - American Society for Virology Student Travel Award for the 25th "Silver Anniversary" Annual Meeting 15-19 July 2006 - University of Wisconsin-Madison.
    • 2006 - van Walree grant for working visit abroad from Royal Netherlands Academy of Arts and Sciences.
    • 2002 - Socrates / Erasmus scholarship for working visit abroad from the Jagiellonian University in Cracow on behalf of the European Comission.

    • 2021- Member of the European expert group on SARS-CoV-2 by the European Comission
    • 2020- Vice-chairman of the advisory board by the president of the Polish Academy of Sciences.
    • 2020- Expert of the Agency for Health Technology Assessment.
    • 2020- Member of the advisory board ”Science Against the Pandemic”
    • 2020-2022 Member of the Medical Advisory board for COVID-19 by the prime minister of Poland.
    • 2020 Member of the governmental advisory board for combating the COVID-19.
    • 26.11.2019 - . Head of the committee for the development of the discipline of biology at the Jagiellonian University.
    • 01.09.2019 - . Member of the Council for the Discipline of Biology. Jagiellonian University.
    • 08.01.2019: Title of professor awarded by the President of the Republic of Poland.
    • 01.12.2018—until now: Professor, Virogenetics Laboratory of Virology, Malopolska Center of Biotechnology, Jagiellonian University, Krakow Poland
    • 01.02.2017-until now: Member of the Malopolska Center of Biotechnology board.
    • 2017-until now: Member of the Committee for Evaluation of Scientific Institutions evaluation team.
    • 01.10.2016—30.11.2018: Professor of the Jagiellonian University at the Microbiology Departament, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 29.10.2013: Habilitation in field of microbiology. Faculty of Biology and Environmental Protection, University of Lodz, Poland.
    • 2012-2016: Member of the Committee for Evaluation of Scientific Institutions evaluation team.
    • 23.09.2012 - 30.09.2012: Scientific visit at the University of North Carolina, Chapel Hill, NC, USA
    • 01.09.2012 - 31.08.2016: Member of the Jagiellonian University Senate
    • 23-27.04.2012: Biosafety BSL3 course at the Health Protection Agency, Porton, United Kingdom
    • 04.07.2009: International Project Management Association (IPMA) certificate: "Certified Project Management Associate"
    • 01.04.2009—30.09.2016: Scientific coordinator at Molecular Biotechnology for Health project, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 01.12.2008—30.09.2016: Assistant Professor at the Microbiology Departament, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 01.10.2008-20.06.2008: professional studies, Project Management; Wyższa Szkola Europejska im. ks. Jozefa Tischnera, Krakow Poland
    • 01.10.2007-30.11.2008: Post-doctoral position at the Microbiology Departament, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Krakow Poland
    • 29.06.2007: PhD Thesis in field od Medical Sciences, specialization of virology. 'Virus discovery and human coronavirus NL63' Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), University of Amsterdam
    • July 2006: Radiation Safety Orientation Course, UNC at Chapel Hill, USA
    • 20.04.2006 - 14.07.2006: 3-month training at the Department of Epidemiology, University of North Carolina, Chapel Hill, United States of America.
    • 01.09.2003 - 29.07.2007: PhD student position at Departments of Human Retrovirology Academic Medical Hospital, University of Amsterdam, Amsterdam, The Netherlands
    • June 2003: Master degree thesis in the field of biotechnology, specialization of molecular biology: ' Oxidative damage of DNA in presence of etoposide and quercetin ' Faculty of Biotechnology, Krakow, Poland
    • 01.02.2003 - 31.05.2003: 4-month training at Departments of Human retrovirology in a framework of Socrates/Erasmus scholarship Academic Medical Hospital, University of Amsterdam, Amsterdam, The Netherlands
    • 1998 - 2003: Jagiellonian University, Department of General Biochemistry, Faculty of Biotechnology, Krakow, Poland
    • 1994 - 1998: Stanislaw Wyspianski High School , Krakow , Poland

    • European Society for Virology
    • American Society of Virology
    • Polish Society for Virology
    • Polish Society for Cell Biology
    • „Polityka” Scholars Association

    1. Botwina, P.; Obłoza, M.; Zatorska-Płachta, M.; Kamiński, K.; Mizusaki, M.; Yusa, S.-I.; Szczubiałka, K.; Pyrc, K.; Nowakowska, M. (2022) Self-Organized Nanoparticles of Random and Block Copolymers of Sodium 2-(acrylamido)-2-methyl-1-propanesulfonate and Sodium 11-(acrylamido)undecanoate as Safe and Effective Zika Virus Inhibitors. Pharmaceutics, 14, 309.
    2. Matsuda A, Plewka J, Chykunova Y, Jones AN, Pachota M, Rawski M, Mourão A, Karim A, Kresik L, Lis K, Minia I, Hartman K, Sonani R, Schlauderer F, Dubin G, Sattler M, Suder P, Popowicz G, Pyrc K, Czarna A. (2022). Despite the odds: formation of the SARS-CoV-2 methylation complex. BiorXiv. doi: https://doi.org/10.1101/2022.01.25.477673
    3. Rabalski L, Kosinski M, Mazur-Panasiuk N, Szewczyk B, Bienkowska-Szewczyk K, Kant R, Sironen T, Pyrc K*, Grzybek M*. (2021). Zoonotic spillover of SARS-CoV-2: mink-adapted virus in humans. Clinical microbiology and infection. S1198-743X(21)00698-4.
    4. Synowiec A, Jedrysik M, Branicki W, Klajmon A, Lei J, Owczarek K, Chen S, Szczepanski A, Wang J, Zhang P, Labaj P, Pyrc K. (2021). Identification of cellular factors required for SARS-CoV-2 replication. Cells. 10(11):3159.
    5. Sancineto L, Ostacolo C, Ortega-Alarcon D, ALESANCO AJ, Ceballos-Laita L, Vega S, Abian O, Velazquez-Campoy A, Moretti S, Dabrowska A, Botwina P, Synowiec A, KulaPacurar A, Pyrc K, Iraci N, Santi C. (2021) Argine improves solubility and anti SARS-CoV-2 Mpro activity of Rutin but not the antiviral activity in cells. Molecules. 6(19):6062.
    6. Mazur-Panasiuk N, Rabalski L, Gromowski T, Nowicki G, Kowalski M, Wydmanski W, Szulc P, Kosinski M, Gackowska K, Drweska-Matelska N, Grabowski J, Piotrowska-Mietelska A, Szewczyk B, Bienkowska-Szewczyk K, Swadzba J, Labaj P, Grzybek M, Pyrc K. Rapid expansion of SARS-CoV-2 Delta variant with an 872 nt deletion encompassing ORF7a, ORF7b and ORF8. Eurosurveillance. 26(39)30/Sep/2021.
    7. Napolitano V, Dabrowska A, Schorpp K, Mourão A, Barreto-Duran E, Benedyk M, Botwina P, Brandner S, Bostock M, Chykunova Y, Czarna A, Dubin G, Fröhlich T, Hoelscher M, Jedrysik M, Matsuda A, Owczarek K, Pachota M, Plettenburg O, Potempa J, Rothenaigner I, Schlauderer F, Szczepanski A, Mohn KGI, Blomberg B, Sattler M*, Hadian K*, Popowicz GM*, Pyrc K*. Acriflavine, a clinically aproved drug, inhibits SARS-CoV-2 and other betacoronaviruses. Cell Chemical Biology. in press.
    8. Pyrc K, Milewska A, Baretto Duran E, Botwina P, Lopes R, Arenas-Pinto A, Badr M, Mellor R, Kalber T, Fernandez-Reyes D, Schatzlein AG, Uchegbu IF. (2020). SARS-CoV-2 inhibition in human airway epithelial cells using a mucoadhesive, amphiphilic chitosan that may serve as an anti-viral nasal spray. Scientific Reports. . 11, 20012.
    9. Mazur-Panasiuk N, Botwina P, Kutaj A, Woszczyna D, Pyrc K. (2021) Ozone Treatment Is Insufficient to Inactivate SARS-CoV-2 Surrogate under Field Conditions.  Antioxidants. 10(9):1480.
    10. Naskalska A, Dabrowska A, Szczepanski A, Jasik KP, Gromadzka B, Pyrc K. (2021) Functional SARS CoV-2 virus-like particles from insect cells. Frontiers in Microbiology. in press.
    11. Sancineto L, Mangiavacchi F, Dabrowska A, Pacuła A, Obieziurska-Fabisiak M, Scimmi C, Lei Y, Kong J, Zhao Y, dos Santos Machado K, Velasque Werhli A, Ciancaleoni G, Nascimento V, Kula-Pacurar A, João Lenardão E, Yang H, Ścianowski J, Pyrc K, Santi C. (2020). Organoselenium mild electrophiles in the inhibition of Mpro and SARS-CoV-2 replication. ChemRxiv. https://doi.org/10.26434/chemrxiv.12994250.v1
    12. Rabalski L, Kosinski M, Mazur-Panasiuk N, Szewczyk B, Bienkowska-Szewczyk K, Kant R, Sironen T, Pyrc K*, Grzybek M*. Zoonotic spillover of SARS-CoV-2: mink-adapted virus in humans. bioRxiv 2021.03.05.433713; doi: https://doi.org/10.1101/2021.03.05.433713
    13. Mangiavacchi F, Botwina P, Menichetti E, Bagnoli L, Rosati O, Marini F, Fonseca SF, Abenante L, Alves D, Dabrowska A, Kula-Pacurar A, Ortega-Alarcon D, Jimenez-Alesanco A, Ceballos-Laita L, Vega S, Rizzuti B, Abian O, Lenardão EJ, Velázquez-Campoy A, Pyrc K, Sancineto L, Santi C. (2021). Seleno functionalization of quercetin improves the antiviral activity against the SARS-CoV-2 through the non-covalent inhibition of Mpro. International Journal of Molecular Sciences. 22(13):7048.
    14. Ciejka J, Grzybala M, Gut A, Szuwarzynski M, Pyrc K, Nowakowska M, Szczubiałka K. (2021). Tuning the Surface Properties of Poly(allylamine hydrochloride)-based Multilayer Films. Materials. 14(9):2361.
    15. Antiviral Cyanometabolites-A Review. (2021) Mazur-Marzec H, Cegłowska M, Konkel R, Pyrć K. Biomolecules. 11(3):474.
    16. Dabrowska A, Milewska A, Ner-Kluza J, Suder P, Pyrc K. (2021). Mass spectrometry versus conventional techniques of protein detection: Zika virus NS3 protease activity towards cellular proteins. Molecules. 26(12):3732.
    17. Lenart M, Pyrc K, Siedlar M. 2021. Can we define CD3+CD56+ cells as NKT cells with impunity? Clinical Immunology. 226:108708.
    18. Synowiec A, Szczepanski A, Barreto-Duran E, Lie LK, Pyrc K. (2021). SARS-CoV-2: A systemic infection. Clinical Microbiology Reviews. 34(2):e00133-20.
    19. Milewska A, Chi Y, Szczepanski A, Barreto-Duran E, Dabrowska A, Botwina P, Liu K, Liu D, Guo X, Ge Y, Li J, Cui L, Ochman M, Urlik M, Rodziewicz-Motowidlo S, Zhu F, Szczubialka K, Nowakowska M, Pyrc K. (2021). HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV. Journal of Virology. 95(4):e01622-20.
    20. First lung transplantation as a treatment of a patient supported with extracorporeal membrane oxygenation (ECMO) after COVID-19 in Poland. (2021). Urlik M, Szułdrzyński K, Stącel T, Nęcki M, Bielański P, Jankowski M, Antończyk R, Latos M, Pióro A, Zembala M, Pyrć K, Ochman M. Adv Respir Med. 2021;89(3):328-333.
    21. Rzymski P, Borkowski L, Drag M, Flisiak R, Jemielity J, Krajewski J, Mastalerz-Migas A, Matyja A, Pyrc K, Simon K, Sutkowski M, Wysocki J, Zajkowska J, Fal A. (2021) The strategies to support the COVID-19 vaccination with evidence-based communication and tackling misinformation. Vaccines. 9(2):109.
    22. Milewska A, Falkowski K, Kulczycka M, Bielecka E, Naskalska A, Mak P, Lesner A, Ochman M, Urlik M, Diamandis E, Prassas I, Potempa J, Kantyka T, Pyrc K. (2020). Kallikrein 13 serves as a priming protease during infection by the human coronavirus HKU1. Science Signaling. 13(659):eaba9902.
    23. Pancer K, Milewska A, Owczarek K, Dabrowska A, Kowalski M, Labaj P, Branicki W, Sanak M, Pyrc K. The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans. (2020). PLoS Pathogens. 16(12):e1008959.
    24. Butowt R, Pyrc K, von Bartheld C. (2020). Battle at the entrance gate: CIITA as a weapon to prevent the internalization of SARS-CoV-2 and Ebola viruses. Signal Transduction and Targeted Therapy.5(1):278.
    25. Milewska A, Ner-Kluza J, Dabrowska A, Bodzon-Kulakowska A, Pyrc K, Suder P. (2020). Mass spectrometry in virological sciences. Mass Spectrometry Reviews. 39(5-6):499-522.
    26. Erik Alm, Eeva K. Broberg, Thomas Connor, Emma Hodcroft, Andrey B. Komissarov, Sebastian Maurer-Stroh, Angeliki Melidou, Richard Neher, Áine O’Toole, Dmitriy Pereyaslov, Ruslan Kalendar, The WHO European Region sequencing laboratories and GISAID EpiCoV group. (2020). Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance. 25(32). 1560-7917.
    27. Milewska A, Kula-Pacurar A, Wadas J, Suder A, Szczepanski A, Dabrowska A, Owczarek K, Marcello A, Ochman M, Stacel T, Rajfur Z, Sanak M, Labaj P, Branicki W, Pyrc K. (2020). Replication of Severe Acute Respiratory Syndrome Coronavirus 2 in Human Respiratory Epithelium. Journal of Virology. 94(15):e00957-20.
    28. Mazzocco G, Niemiec I, Myronov A, Skoczylas P, Kaczmarczyk J, Sanecka-Duin A, Gruba K, Król P, Drwal M, Szczepanik M, Pyrc K, Stępniak P. (2020). AI aided design of epitope-based vaccine for the induction of cellular immune responses against SARS-CoV-2. Frontiers in Genetics. 12;602196.
    29. Kula-Pacurar A, Wadas J, Suder A, Szczepanski A, Milewska A, Ochman M, Stacel T, Pyrc K. (2020). Visualization of SARS-CoV-2 Using Immuno RNA-Fluorescence In Situ Hybridization. JoVE. 166.
    30. Białobrzeska W, Firganek D, Czerkies M, Lipniacki T, Skwarecka M, Dziąbowska K, Cebula Z, Malinowska N, Bigus D, Bięga E, Pyrc K, Pala K, Żołędowska S, Nidzworski D. (2020). Electrochemical immunosensors based on screen-printed gold and glassy carbon electrodes. Comparison of performance for Respiratory Syncytial Virus detection. Biosensors. 10(11):175.
    31. Milewska A, Owczarek K, Szczepanski A, Pyrc K. (2020). Visualizing Coronavirus Entry into Cells. Methods in Molecular Biology. 2203:241-261.
    32. Botwina P, Obłoza M, Szczepański A, Szczubiałka K, Nowakowska M, Pyrc K. (2020). In Vitro Inhibition of Zika Virus Replication with Poly(Sodium 4-Styrenesulfonate). Viruses. 12(9):E926.
    33. Ghafouri-Fard S, Noroozi R, Vafaee R, Branicki W, Poṡpiech E, Pyrc K, Labaj P, Omrani MD, Taheri M, Sanak M. (2020). Effects of host genetic variations on response to, susceptibility and severity of respiratory infections. Biomedicine & Pharmacotherapy. 128, 110296.
    34. Ghafouri-Fard S, Noroozi R, Omrani D, Branicki W, Pośpiech E, Sayada A, Pyrc K, Labaj P, Vafaee R, Taheri M, Sanak M. (2020). Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection. Vascular Pharmacology. 130, 106680.
    35. Noroozi R, Branicki W, Pyrc K, Labaj P, Pospiech E, Taheri M, Ghafouri-Fard S. (2020). Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions. Cytokine 133, 155143
    36. Stącel T, Nęcki M, Antończyk R, Latos M, Urlik M, Kościołek J, Kordylewska-Kubus A, Litewka J, Przybyłowski P, Zawadzki F, Wajda-Pokrontka M, Pyrc K, Zembala M, Ochman M. (2020). Effectiveness of Lung Transplantation in Patients With Interstitial Lung Diseases. Transplant Proc. 52(7):2143-2148.
    37. Ghafouri-Fard S, Noroozi R, Omarani MD, Branicki W, Pośpiech E, Sayad A, Pyrc K, Łabaj P, Vafaee R, Taheri M, Sanak M. (2020). Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection. Vascular Pharmacology. 130:106680.
    38. Rotter A, Bacu A, Barbier M, Bertoni F, Bones AM, Cancela ML, Carlsson J, Carvalho MF, Cegłowska M, Dalay MC, Dailianis T, Deniz I, Drakulovic D, Dubnika A, Einarsson H, Erdoğan A, Eroldoğan OT, Ezra D, Fazi S, FitzGerald RJ, Gargan LM, Gaudêncio SP, DeNardis NI, Joksimovic D, Kataržytė M, Kotta J, Mandalakis M, Matijošytė I, Mazur-Marzec H, Massa-Gallucci A, Mehiri M, Nielsen SL, Novoveská L, Overlingė D, Portman ME, Pyrc K, Rebours C, Reinsch T, Reyes F, Rinkevich B, Robbens J, Rudovica V, Sabotič J, Safarik I, Talve S, Tasdemir D, Schneider XT, Thomas OP, Toruńska-Sitarz A, Varese GC, Vasquez MI. (2020). A New Network for the Advancement of Marine Biotechnology in Europe and Beyond. Frontiers in Marine Science. 7;278.
    39. Botwina P, Owczarek K, Rajfur Z, Ochman M, Urlik M, Nowakowska M, Szczubiałka K, Pyrc K. (2020). Berberine hampers influenza A replication through inhibition of MAPK/ERK pathway. Viruses. 12(3):344. doi: 10.3390/v12030344.
    40. Pachota M, Kłysik-Trzciańska K, Synowiec A, Yukioka S, Yusa S, Zając, M, Zawilinska B, Dzieciątkowski T, Szczubiałka K, Pyrc K*, Nowakowska M*. (2019). Highly effective and safe polymeric inhibitors of herpes simplex virus in vitro and in vivo. ACS Applied Materials & Interfaces. 11(30):26745-26752.
    41. Owczarek K, Chykunova Y, Jassoy C, Maksym B, Rajfur Z, Pyrc K. (2019) Zika virus: mapping and reprogramming the entry. (2019). Cell Communication and Signaling. 17(1):41.
    42. Naskalska A, Dabrowska A, Szczepanski A, Milewska A, Jasik K, Pyrc K*.  (2019). Membrane protein of HCoV-NL63 is responsible for interaction with the adhesion receptor. Journal of Virology. 93(19):e00355-19.
    43. Synowiec A, Gryniuk I, Pachota M, Strzelec L, Roman O, Kłysik-Trzciańska K, Zając M, Drebot I, Gula K, Andruchowicz A, Rajfur Z, Szczubiałka K, Nowakowska K*, Pyrc K. (2019). Cat flu: broad spectrum polymeric antivirals. Antiviral Research. 170:104563.
    44. Labuz K, Adamowicz P, Kała M, Pyrc K, Reszke E, Mielczarek P, Silberring J, Smoluch M*. (2019). Detection of legal highs in the urine of methadone-treated patient by LC-MS. Basic and clinical pharmacology and toxicology. 125(3):253-258.
    45. Szczepanski A, Owczarek K, Bzowska K, Gula K, Drebot I, Ochman M, Maksym B, Rajfur Z, Mitchell JA, Pyrc K. (2019) Canine Respiratory Coronavirus, Bovine Coronavirus and Human Coronavirus OC43: Receptors and attachment factors. Viruses. 11(4):328.
    46. Ciejka J, Botwina P, Nowakowska M, Szczubiałka K, Pyrc K. (2019) Synthetic sulfonated derivatives of poly(allylamine hydrochloride) as inhibitors of human metapneumovirus. PLoS One. 14(3):e0214646..
    47. Gruba N, Igancio Rodrigez MJ, Wysocka M, Skorenski M, Grzywa R, Dabrowska A, Lecka M, Suder P, Sienczyk M, Pyrc K, Lesner A. (2018). One step beyond: design of substrates spanning primed positions of Zika virus NS2B-NS3 protease. ACS Medicinal Chemistry Letters. 9(10):1025-1029.
    48. Naskalska A, Dabrowska A, Nowak P, Szczepanski A, Jasik K, Milewska A, Ochman M, Zeglen S, Rajfur Z, Pyrc K. (2018). Novel coronavirus like particles targeting cells lining the respiratory tract. PLoS One. 13(9):e0203489.
    49. Wojarski J, Ochman M, Latos M, Biniszkiewicz P, Karolak W, Woźniak-Grygiel E, Maruszewski M, Urlik M, Mędrala W, Kułaczkowska Z, Pyrc K, Żegleń S. (2018). Immunosuppressive Treatment and Its Effect on the Occurrence of Pneumocystis jiroveci, Mycoplasma pneumoniae, Chlamydophila pnemoniae, and Legionella pneumophila Infections/Colonizations Among Lung Transplant Recipients. Transplantation Proceedings. 50(7):2053-2058.
    50. Skorenski M, Milewska A, Pyrc K, Sienczyk M, Oleksyszyn J. (2018). Phosphonate inhibitors of West Nile virus NS2B/NS3 protease. Journal of Enzyme Inhibition and Medicinal Chemistry. 34(1):8-14.
    51. Szczepanski A, Owczarek K, Milewska A, Baster Z, Rajfur Z, Mitchell J, Pyrc K. (2018) Canine respiratory coronavirus employs caveolin-1-mediated pathway for internalization to HRT-18G cells. Veterinary Research. 49:55
    52. Owczarek K, Szczepanski A, Milewska A, Baster Z, Rajfur Z, Sarna M, Pyrc K. (2018) Early events during human coronavirus OC43 entry to the cell. Scientific Reports. 8(1):7124.
    53. Milewska A, Kindler E, Vkovski P, Zeglen S, Ochman M, Thiel V, Rajfur Z, Pyrc K.(2018) APOBEC3-mediated restriction of RNA virus replication. Scientific Reports. in press.
    54. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS (2017) Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Science Translational Medicine. Vol. 9, Issue 396, eaal3653.
    55. A Milewska, P Nowak, K Owczarek, A Szczepanski, M Zarebski, A Hoang-Bujnowicz, K Berniak, J Wojarski, S Zeglen, Z Baster, Z Rajfur, Pyrc K (2017) Entry of human coronavirus NL63 to the cell. Journal of Virology. 92(3). pii: e01933-17.
    56. Pachota M, Klysik K, Synowiec A, Ciejka J, Szczubialka K, Pyrc K, Nowakowska M. (2017) Inhibition of herpes simplex viruses by cationic dextran derivatives. Journal of Medicinal Chemistry. 60(20):8620-8630.
    57. Skalniak L, Zak K, Guzik K, Magiera K, Musielak B, Pachota M, Szelazek B, Kocik J, Grudnik P, Tomala M, Krzanik S, Pyrc K, Dömling A, Dubin G, Holak T. (2017) Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget. 8(42):72167-72181.
    58. Szelazek B, Kabala W, Kus K, Zdzalik M, Twarda-Clapa A, Golik P, Burmistrz M, Florek D, Wladyka B, Pyrc K, Dubin G. (2017) Structural characterization of HCoV‑NL63 N-protein. Journal of Virology. 91(11). pii: e02503-16.
    59. Ciejka J, Wolski K, Nowakowska M, Pyrc K, Szczubiałka K. (2017) Biopolymeric nano/microspheres for selective and reversible adsorption of coronaviruses. Materials Science & Engineering C. 76, 735–742.
    60. Burmistrz M, Rodriguez Martinez JI, Krochmal D, Staniec D, Pyrc K. (2017) crRNAs in Porphyromonas gingivalis CRISPR-Cas I-C system. Journal of Bacteriology. 199(23). pii: e00275-17.
    61. Skorenski M, Pachota M, Pyrc K, Sienczyk M, Oleksyszyn J (2017) Novel Peptidyl α-Aminoalkylphosphonates as Inhibitors of Hepatitis C Virus NS3/4A Protease. Antiviral Research. 144:286-298.
    62. Szczubialka K., Pyrc K., Nowakowska M. (2016) In search for effective and definitive treatment of Herpes Simplex Virus Type 1 (HSV-1) infections. RSC Advances. 6, 1058-1075.
    63. Ciejka J, Milewska A, Wytrwal M, Wojarski J, Golda A, Ochman M, Nowakowska M, Szczubialka K, Pyrc K. (2016) Novel polyanions inhibiting replication of influenza viruses. Antimicrobial Agents and Chemotherapy (AAC). 60(4):1955-66.
    64. Benedyk M., Mydel P., Płaza K., Gawron K., Milewska A., Maresz K., Koziel J., Jotwani R., Pyrc K., Potempa J. (2016) Gingipains: critical factors in the development of aspiration pneumonia caused by Porphyromonas gingivalis. Journal of Innate Immunity. 8(2):185-98.
    65. Gruba N*, Rodriguez Martinez JI*, Grzywa R, Wysocka M, Skoreński M, Burmistrz M, Łęcka M, Lesner A, Sieńczyk M, Pyrc K. (2016) Substrate profiling of Zika virus NS2B-NS3 protease. FEBS Letters. 590(20):3459-3468.
    66. Szychowska M, Siwek W, Pawolski D, Karani AA, Pyrc K, Bochtler M (2016) Type III CRISPR complexes from Thermus thermophilus. Acta Biochimica Polonica. 63(2):377-86.
    67. Milewska A, Kaminski K, Ciejka J, Kosowicz K, Zeglen S, Wojarski J, Nowakowska M, Szczubialka K, Pyrc K (2016) HTCC: broad range inhibitor of coronavirus entry. PLoS One. 11(6):e0156552.
    68. Huang X, Dong W, Milewska A, Golda A, Qi Y, Zhu Q, Marasco W, Baric R, Sims A, Pyrc K, Li W, Sui J. (2015). HCoV-HKU1 Spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs HE protein as a receptor-destroying enzyme. Journal of Virology. 89(14):7202-13.
    69. Zabieglo K, Majewski P, Majchrzak-Gorecka M, Wlodarczyk A, Grygier B, Zegar A, Kapinska-Mrowiecka M, Naskalska A, Pyrc K, Dubin A, Wahl S, Cichy J. (2015). The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps. Journal of Leukocyte Biology. 98(1):99-106.
    70. Burmistrz M, Dudek B, Staniec D, Rodriguez Martinez JI, Bochtler M, Potempa J, Pyrc K. (2015). Functional analysis of Porphyromonas gingivalis W83 CRISPR-Cas systems. Journal of Bacteriology. 197(16):2631-41.
    71. Burmistrz M, Pyrc K. (2015). CRISPR/Cas systems in prokaryotes. Polish Journal of Microbiology. 64(3):193-202.
    72. Pyrc K. (2015). Ludzkie koronawirusy. Postępy Nauk Medycznych. t. XXVIII, nr 4B, 2015.
    73. Naskalska A, Pyrc K. (2015) Virus Like Particles as Immunogens and Universal Nanocarriers. Polish Journal of Microbiology. 64(1):3-13.
    74. Zuwala K, Golda A, Kabala W, Burmistrz M, Zdzalik M, Nowak P, Kedracka-Krok S, Zarebski M, Dobrucki J, Florek D, Zeglen S, Wojarski J, Potempa J, Dubin G, Pyrc K. (2015) The nucleocapsid protein of human coronavirus NL63. PLoS One. 20;10(2):e0117833.
    75. Milewska A, Zarebski M, Nowak P, Stozek K, Potempa J, Pyrc K. (2014) Human coronavirus NL63 utilize heparan sulfate proteoglycans for attachment to target cells. Journal of Virology. 88(22):13221-30.
    76. Koziel J, Bryzek D, Sroka A, Maresz K, Glowczyk I, Bielecka E, Kantyka T, Pyrc K, Svoboda P, Pohl J, Potempa J. (2014) Citrullination Alters Immunomodulatory Function of LL-37 Essential for Prevention of Endotoxin-Induced Sepsis. Journal of Immunology. 2014 Apr 25.
    77. Gawron K, Łazarz–Bartyzel K, Łazarz M, Stęplewska K, Pyrc K, Potempa J, Chomyszyn–Gajewska M. (2014) In vitro testing the potential of a novel chimeric IgG variant for inhibiting collagen fibrils formation in recurrent hereditary gingival fibromatosis. Journal of Physiology and Pharmacology. 65(4):585-91.
    78. Florek D, Burmistrz M, Potempa J, Pyrc K. Stability of infectious human coronavirus NL63 (2014) Journal of Virological Methods. S0166-0934(14)00136-0.
    79. Maresz K, Hellvard A, Sroka A, Adamowicz K, Bielecka E, Koziel J, Gawron K, Mizgalska D, Marcinska K, Benedyk M, Pyrc K, Quirke A, Jonsson R, Alzabin S, Venables P, Nguyen K, Mydel P, Potempa J. Porphyromonas gingivalis Facilitates the Development and Progression of Destructive Arthritis through Its Unique Bacterial Peptidylarginine Deiminase (PAD). (2013) PloS Pathogens. 9(9): e1003627.
    80. Milewska A, Ciejka J, Kaminski K, Karewicz A, Bielska D, Zeglen S, Karolak W, Nowakowska M, Potempa J, Bosch BJ, Pyrc K, Szczubialka K (2013) Novel polymeric inhibitors of HCoV-NL63. Antiviral Research. 97(2):112-21.
    81. Pyrc K, Milewska A, Kantyka T, Sroka A, Maresz K, Kozieł J, Nguyen KA, Enghild JJ., Knudsen AD, Potempa J. (2013) Inactivation of epidermal growth factor by Porphyromonas gingivalis as a potential mechanism for periodontal tissue damage. Infection and Immunity, 81(1):55.
    82. Kantyka T*, Pyrc K*, Gruca M, Smagur J, Plaza K, Guzik K, Zeglen S, Ochman M, Potempa J. (2013) Staphylococcus aureus proteases degrade lung surfactant protein A potentially impairing innate immunity of the lung. Journal of Innate Immunity. 5(3):251-60.
    83. Dubin G, Koziel J., Pyrc K., Wladyka B., Potempa J. (2013) Bacterial proteases in disease – role in intracellular survival, evasion of coagulation/fibrinolysis innate defenses, toxicoses and viral infections. Current Pharmaceutical Design. 19(6):1090-113.
    84. Pyrc K, Stozek K, Galan W, Potempa J. (2013) HexaPrime: a novel method for detection of coronaviruses. Journal of Virological Methods. 188 (1–2), 29–36.
    85. Milewska A, Pyrc K, Human RIG-1/Mda5 and TLR3 signaling pathways and their role in antiviral response during mucosal infections, Recent Research Developments in Virology, (2012) ISBN: 978-81-7895-563-6, Transworld Research Network.
    86. Dijkman R, Jebbink MF, Deijs M, Milewska A, Pyrc K, Buelow E, van der Bijl A, van der Hoek L. (2012) Replication dependent downregulation of cellular ACE2 protein expression by Human Coronavirus NL63. Journal of General Virology. 93(Pt 9):1924-9.
    87. Pyrc K, Stozek K, Wojcik K, Gawron K, Zeglen S, Karolak W, Wojarski J, Ochman M, Hubalewska-Mazgaj M, Bochenek G, Sanak M, Zembala M, Szczeklik A, Potempa J. (2012) Use of Sensitive, Broad-Spectrum Molecular Assays and Human Airway Epithelium Cultures for Detection of Respiratory Pathogens. PLoS ONE 7(3): e32582.
    88. Pyrc K, Strzyz P, Milewska A, Golda A, Schildgen O, Potempa J. (2011) Porphyromonas gingivalis enzymes enhance infection with human metapneumovirus in vitro. Journal of General Virology. 92(10):2324-32.
    89. Pyrc K, Milewska A, Potempa J. (2011) Development of loop-mediated isothermal amplification assay for detection of human coronavirus-NL63. Journal of Virological Methods. 175(1): 133-136.
    90. Golda A, Malek N, Dudek B, Zeglen S, Wojarski J, Ochman M, Kucewicz E, Zembala M, Potempa J, Pyrc K (2011) Infection with human coronavirus NL63 enhances streptococcal adherence to epithelial cells. Journal of General Virology. 92(6):1358-68.
    91. Pyrc K, Sims AC, Dijkman R, Jebbink M, Long C, Deming D, Donaldson E, Vabret A, Baric R, van der Hoek L, Pickles R (2010) Culturing the Unculturable: Human Coronavirus HKU1 Infects, Replicates, and Produces Progeny Virions in Human Ciliated Airway Epithelial Cell Cultures. Journal of Virology. 84(21):11255-63.
    92. 2008-2009: setting up the virology lab in Poland, organization of the research team.
    93. de Vries M, Pyrc K, Berkhout R, Vermeulen-Oost W, Dijkman R, Jebbink MF, Bruisten S, Berkhout B, van der Hoek L (2008) Human parechovirus type 1, 3, 4, 5 and 6 detection in picornavirus cultures. Journal of Clinical Microbiology. 46(2):759-62.
    94. Dijkman R, Jebbink MF, El Idrissi NB, Pyrc K, Muller MA, Kuijpers TW, Zaaijer HL, van der Hoek L. (2008) Human coronavirus NL63 and 229E seroconversion in children. Journal of Clinical Microbiology. 46(7):2368-73.
    95. Pyrc K (2008) Ludzki koronawirus NL63 - Obraz kliniczny i charakterystyka molekularna. Postepy Mikrobiologii, 47(3) 257-262.
    96. Golda A, Pyrc K (2008) Recent antiviral strategies against human coronavirus – related respiratory illness. Current Opinions in Pulmonary Medicine. 14(3):248-53.
    97. Pyrc K, Jebbink MF, Berkhout B, van der Hoek L. (2008) Detection of new viruses by VIDISCA: virus discovery based on cDNA-amplified fragment length polymorphism. in: SARS-and Other Coronaviruses, Laboratory Protocols. Methods in Molecular Biology, Vol. 454, Ed. Cavanagh, Dave, ISBN: 978-1-58829-867-6.
    98. Pyrc K, Berkhout B, van der Hoek L#. (2007) Identification of new human coronaviruses. Expert Review of Anti-infective Therapy. 5(2):245-253.
    99. Pyrc K#, Berkhout B, van der Hoek L. (2007) Antiviral Strategies Against Human Coronaviruses, Infectious Disorders - Drug Targets. 7(1): 59-66.
    100. Pyrc K#, van der Hoek L#. (2007) Human Coronavirus NL63, a Long Lost Brother, Coronaviruses: Molecular and Cellular Biology. ISBN: 978-1-904455-16-5.
    101. Pyrc K, Berkhout B, and van der Hoek L#. (2007) The novel human coronaviruses NL63 and HKU1. Journal of Virology. 81(7):3051-7.
    102. Pyrc K, Dijkman R, Deng L, Jebbink MF, Ross HA, Berkhout B van der Hoek L#. (2006) Mosaic structure of human coronavirus NL63, one thousand years of evolution. Journal of Molecular Biology. 364(5):964-73.
    103. Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, and van der Hoek L. (2006) Inhibition of Human Coronavirus NL63 Infection at Early Stages of the Replication Cycle. Antimicrobial Agents and Chemotherapy. 50(6): 2000-2008.
    104. van der Hoek L, Pyrc K, Berkhout B. (2006) Human coronavirus NL63, a new respiratory virus. FEMS Microbiology Reviews. 30(5): 760-773.
    105. Dijkman R, Jebbink MF, Wilbrink B, Pyrc K, Zaaijer HL, Minor PD, Franklin S, Berkhout B, Thiel V, van der Hoek L#. (2006) Human coronavirus 229E encodes a single ORF4 protein between the spike and the envelope genes. Virology Journal. 3(1):106.
    106. van der Hoek L, Pyrc K, Berkhout B. (2006) Coronavirus NL63, the new Dutch. Tijdschrift voor Infectieziekten. 1(3):108-114.
    107. Schildgen O#, Jebbink MF, de Vries M, Pyrc K, Dijkman R, Simon A, Muller A, Kupfer B, van der Hoek L. (2006) Identification of cell lines permissive for human coronavirus NL63. Journal of Virological Methods. 138(1-2):207-10.
    108. van der Hoek L, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, Petersen G, Forster J, Berkhout B, Uberla K. (2006) Human coronavirus NL63 infection is associated with croup. Advances in experimental medicine and biology. 581:485-91.
    109. Pohlmann S, Gramberg T, Wegele A, Pyrc K, van der Hoek L, Berkhout B, Hofmann H. (2006) Interaction between the spike protein of human coronavirus NL63 and its cellular receptor ACE2. Advances in experimental medicine and biology. 581:281-4.
    110. Hofmann H, Marzi A, Gramberg T, Geier M, Pyrc K, van der Hoek L, Berkhout B, Pohlmann S. (2006) Attachment factor and receptor engagement of SARS coronavirus and human coronavirus NL63. Advances in experimental medicine and biology. 581:219-27.
    111. Piotrowski Y, van der Hoek L, Pyrc K, Berkhout B, Moll R, Hilgenfeld R. (2006) Nonstructural proteins of human coronavirus NL63. Advances in experimental medicine and biology. 581:97-100.
    112. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S#. (2005) Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. PNAS Proceedings of the National Academy of Sciences, USA. 102(22):7988-93.
    113. van der Hoek L#, Sure K, Ihorst G, Stang A, Pyrc K, Jebbink MF, Petersen G, Forster J, Berkhout B, Uberla K. (2005) Croup Is Associated with the Novel Coronavirus NL63. PLoS Medicine. 2(8):e240.
    114. Pyrc K, Berkhout B, van der Hoek L#. (2005) Molecular characterization of human coronavirus NL63. Recent Research in Infection and Immunity, Transworld Research Network. 3:25-48 ISBN: 81-7895-182-7.
    115. Moes E, Vijgen L, Keyaerts E, Zlateva K, Li S, Maes P, Pyrc K, Berkhout B, van der Hoek L, Van Ranst M#. (2005) A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium. BMC infectious diseases. 5(1):6.
    116. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, Wertheim-van Dillen PM, Kaandorp J, Spaargaren J, Berkhout B#. (2004) Identification of a new human coronavirus. Nature Medicine. 10(4):368-73.
    117. Pyrc K, Jebbink MF, Berkhout B, van der Hoek L#. (2004) Genome structure and transcriptional regulation of human coronavirus NL63. Virology Journal. 1(1):7.
    118. Kapiszewska M#, Pyrc K. (2003) Anticancer and antiartherioslosis action of flavonoids. Vegetables and fruits in the nutrition. Medycyna i Społeczeństwo, Acta Academiae Modrevianae, pp. 101-108.


     NumberDateCountryTitle
    12019-01-15PolandSufonated polystyrens as inhibitors of feline calicivirus
    217P43187PL002018-12-03PolandSufonated polystyrens as inhibitors of feline herspesvirus
    3P.4248712018-03-14PolandUse of copolimers for the treatment of infections caused by HSV-1 virus.
    4PCT/IB2015/055727
    EP 15763979.0
    CA 2,955,406    		2015-07-29
    2017-01-04
    2017-01-17    		PCT
    Europe
    Canada
    		Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative.
    5P 416749
    PCT/IB2017/051918    		2016-04-04
    2017-04-04    		Poland
    PCT    		The use of cationic derivative of dextran for inhibition of herpes simplex viruses.
    6PCT/PL2013/000064
    CA 5885-06-13
    US 14/401,921
    K 2014-7031937
    CN 201380025835.2
    8054/CHENP/2014    		2013-05-16
    2014-11-10
    2014-11-18
    2014-11-14
    2014-11-17
    2014-11-03    		PCT
    Canada
    USA
    Korea
    China
    India    		The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses.

     NumberDateCountryTitle
    1US 9,925,2152018-03-27USAAnionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as a medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV),and infection by influenza virus type A (IAV), and pharmaceutical composition comprising the anionically modified polyallylamine derivative
    2PL 2293522018-02-06PolandN-sulfonic derivative of polyallylamine, application of N-sulfonic derivative of polyallylamine as a medicine, preferably for the prevention and treatment of infection of respiratory tract induced by the rhinoviruses and the pharmaceutical composition containing the N-sulfonic derivate of polyallylamine
    3PL 225045
    EP 2849763
    JP 6177893    		2016-08-12
    2017-05-31
    2017-07-03    		Poland
    Europe
    Japan    		The use of chitosan polymer in the treatment and prevention of infections caused by coronaviruses
    4P.4090162017-11-17PolandN-sulfonic derivative of polyallylamine, application of N-sulfonic derivative of polyallylamine as a medicine, preferably for the prevention and treatment of infection by influenza type A (IAV) virus and the pharmaceutical composition containing the N-sulfonic derivate of polyallylamine.
    5P.4090152017-10-05PolandN-sulfonic derivative of polyallylamine, application of N-sulfonic derivative of polyallylamine as a medicine, preferably for the prevention and treatment of infection of respiratory tract induced by the human metapneumovirus (hMPV) and the pharmaceutical composition containing the N-sulfonic derivate of polyallylamine
    6PL 2256332016-10-05PolandMethod for identification of RNA viruses and the application of the method.

    • long/ultra distance running
    • diving
    • mountaineering
    • sailing